Psoriasis is an inflammatory skin disease affecting approximately 2% of the population, and approximately one-third of patients experience generalized psoriasis ( ). Current treatment options include topical medications, ultraviolet B and oral psoralen with ultraviolet A phototherapy, biologic agents, non-biologic systemic medications, and combinations of the aforementioned. Phototherapy treatment, although effective for many patients, often is inconvenient, requiring three treatments weekly for 2-3 months in order to achieve significant improvement in a patient's psoriasis. The newer biologic medications, while effective in many patients, work by systemic immunosuppression with increased risk of malignancies, infections including tuberculosis and histoplasmosis, congestive heart failure, lupus-like syndrome, demyelinating diseases, etc. In addition to side effects from systemic immunosuppression, non-biologic systemic agents can have major organ toxicity as a potential side effect including bone marrow suppression, liver toxicity, kidney toxicity, etc.